Sequential Proteolysis by Γ-Secretase and Its Implications for Alzheimer's

Total Page:16

File Type:pdf, Size:1020Kb

Sequential Proteolysis by Γ-Secretase and Its Implications for Alzheimer's Sequential Proteolysis by γ-Secretase and Its Implications for Alzheimer’s Disease The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Fernandez, Marty. 2015. Sequential Proteolysis by γ-Secretase and Its Implications for Alzheimer’s Disease. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:17467510 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Sequential proteolysis by !-secretase and its implications for Alzheimer’s disease A dissertation presented by Marty Alyse Fernandez to The Division of Medical Sciences in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Biological Chemistry and Molecular Pharmacology Harvard University Cambridge, Massachusetts May 2015 2015 - Marty Alyse Fernandez All rights reserved. Dissertation Advisor: Dr. Michael S. Wolfe Marty Alyse Fernandez Sequential proteolysis by !-secretase and its implications for Alzheimer’s disease Abstract The production and aggregation of the amyloid !-peptide (A!) is thought to play a central role in Alzheimer’s disease (AD) pathogenesis. The presenilin (PS)-containing "-secretase complex cleaves the amyloid !-protein precursor C-terminal fragment (APP CTF!) to generate A!s of 38-49 residues. Evidence suggests that these A!s are the result of successive "-secretase cleavages, which are thought to start at the # sites to generate A!48 or A!49, followed by C- terminal trimming mostly every three residues to produce secreted A!s. Specifically, two product lines have been proposed: the A!49-46-43-40 line and the A!48-45-42-38 line. An increased proportion of aggregation-prone A!42 compared to A!40 is believed to be important in AD pathogenesis. Despite the apparent relevance of the production of the A! C-terminus in AD, questions surround the mechanisms by which "-secretase generates the A! spectrum and how familial AD-causing (FAD) mutations alter A! production. This dissertation first examined the C-terminal trimming function of "-secretase and how PS FAD mutations alter this activity. We found that synthetic A!49, A!48, A!46, and A!45 are trimmed to A!40 and A!42 by "-secretase in vitro. Moreover, our results were consistent with the two-pathway model in which A!49 is primarily converted to A!40 and A!48 to A!42, but also demonstrated a small degree of crossover between the pathways. Most importantly, we iii found that PS1 FAD mutations dramatically reduce the efficiency of trimming of #-cleaved A!s, particularly the trimming of A!49 to A!40. We also investigated substrate determinants for # site endoproteolysis and C-terminal trimming of APP CTF! by "-secretase. The deletion of residues around the # sites indicated that upstream sequences, and not depth within the transmembrane domain, are the determinants of # site specificity. We also show that instability of the APP CTF! transmembrane helix near the # site increases endoproteolysis, and that instability near the carboxypeptidase cleavage sites facilitates C-terminal trimming by "-secretase. Last, the potential role of A!45-49 in AD pathogenesis was considered. We did not detect these A! species in AD brains by immunoprecipitation and western blot. However, we developed cellular systems to investigate their toxicity and obtained preliminary data suggesting that these A!s may be neurotoxic. iv TABLE OF CONTENTS Title Page Prefix: Table of figures and tables vi Acknowledgements and dedication viii Chapter 1: Introduction 1 Chapter 2: Alzheimer presenilin-1 mutations dramatically reduce trimming of 39 long amyloid !-peptides (A!) by "-secretase to increase 42-to-40-residue A! Chapter 3: Transmembrane substrate determinants for "-secretase processing 76 of APP CTF! Chapter 4: Investigation of the pathogenicity of #- and $-cleaved A! peptides 119 Chapter 5: Conclusions and future directions 149 Appendix: Supplementary figures 163 v TABLE OF FIGURES AND TABLES Figure Title Page Figure 1.1 Proteolytic processing of APP by %-, !-, and "-secretases 4 Figure 1.2 The components of the "-secretase complex 13 Figure 1.3 Dual "-secretase cleavage sites within APP CTF! 18 Figure 1.4 "-secretase processing of the APP CTF! transmembrane domain 20 Figure 2.1 "-secretase trims synthetic A!49 and A!48 to A!40 and A!42 in vitro 47 Figure 2.2 "-secretase modulators lower A!42 produced from A!49 and A!48 50 Table 2.1 A!42/A!40 ratios from trimming of #- and $-cleaved A!s 52 Figure 2.3 "-secretase trims p3/A!49 and p3/A!48 to p3/A!40 and p3/A!42 54 in cells Figure 2.4 "-secretase trims synthetic A!45, A!46, and A!47 to A!40 and A!42 56 in vitro Figure 2.5 A!49 and A!48 conversions to A!40 and A!42 by "-secretase are 59 dramatically reduced by PS1 FAD mutations Table 2.2 Vmax and Km of A! trimming events from WT and PS1 FAD-mutant 61 "-secretase Table 2.3 Catalytic efficiencies of trimming of A!49 and A!48 to A!40 and A!42 63 as a percent of WT PS1 Table 2.4 Rate of trimming A!46 and A!49 to A!40 as a percent of WT PS1 65 Figure 2.6 FAD-mutant PS1-"-secretase complexes increase A!42/40 independent 67 of effects on #-site endoproteolysis Figure 3.1 "-secretase trims A!49 and A!49 with a C-terminal amide to generate 85 primarily A!40 Figure 3.2. "-secretase has S1’, S2’, and S3’ pockets 88 vi Figure 3.3. Deletion of residues around the # sites does not alter the primary A! 90 cleavage products Figure 3.4. Depth within the transmembrane domain is not a determinant of 93 #-site specificity Figure 3.5. Helical instability between the # and $ sites is important for 97 endoproteolysis at the # site Figure 3.6. Helical instability between the # and $ sites and trimming 99 Figure 3.7. Helical instability between $ and " sites and " and "’ site does not 101 affect endoproteolysis at the # site Figure 3.8. Helical propensity between $ and " sites and " and "’ sites and 103 trimming Figure 4.1 A!45-49 are primarily in the cell membrane 129 Figure 4.2 Analysis of A!45-49 in AD brain samples 131 Figure 4.3 Development of inducible APP$- and APP#-expressing N2a cell lines 135 Figure 4.4 Analysis of long A! toxicity in differentiated SH-SY5Y cells 137 Figure S1 Mass spectrometric analysis of the A!s generated from CTF! 164 deletion mutants Figure S2 Mass spectrometric analysis of the A!s generated from # to $ site 166 helical stability mutant CTF!s Figure S3 Mass spectrometric analysis of the A!s generated from $ to " site 167 and " to " ‘ site helical stability mutant CTF!s vii Acknowledgements I would first like to thank Dr. Wolfe for allowing me to work on these projects and for being a patient, enthusiastic, and generous mentor and teacher. I am very lucky to have found a lab to join with a PI who is motivated not only by an endless interest in science, but also by a genuine desire to help people. Dr. Wolfe was always available for advice on problems large and small, and if I ever went into a meeting feeling anxious or discouraged by experimental troubles or negative results, I would always leave more excited than before to pursue a solution or new idea that had come up. In my mind, this is a sign of a great mentor. I also thank my labmates, who have been both friends and teachers to me. It has been a wonderful experience working with people who are always willing to help and who are happy to share their extensive knowledge and expertise. I could not have asked for a better group of people to have worked with and to have celebrated publications, new jobs, weddings, and birthdays with throughout the years. I also thank my colleagues in the CND for being an extension of my lab, always willing to help and great friends. They were also kind (or, should I say unkind?!) enough to select me as the involuntary president of the CND “Beer Camp,” during which we shared many a fun evening. I thank all of the students I had the opportunity to mentor for all of their hard work in the lab, their refreshing enthusiasm that was heart-warming to see on days that I was discouraged by failed experiments, and for allowing me to learn about teaching and managing students. I also thank my advisory committee. As a nervous student embarking on my PhD, I never thought I would say that committee meetings were fun, but my advisors were able to accomplish just that with their sage advice and thought-provoking conversations. I also thank my classmates in the viii BBS program for often teaching me as much as the class lecturers and for always being willing to lend a hand. Most importantly, I thank my family. I am indebted to my parents for their endless love, support, and encouragement. They instilled in me the importance of learning and doing well in school, and taught by example the value of working hard. I thank my brother for being my first and most loyal friend, my friends and extended family for making my life rich and fun, and my friends in Boston for making this city a home.
Recommended publications
  • Amyloidogenic Processing of the Human Amyloid Precursor Protein in Primary Cultures of Rat Hippocampal Neurons
    The Journal of Neuroscience, February 1, 1996. 16(3):699-908 Amyloidogenic Processing of the Human Amyloid Precursor Protein in Primary Cultures of Rat Hippocampal Neurons Mikael Simons,1s2 Bart De Strooper, 2,s Gerd Multhaup,’ Pentti J. Tienari,l** Carlos G. Dot@* and Konrad Beyreutherl 1Center for Molecular Biology Heidelberg, University of Heidelberg, D-69 120 Heidelberg, Germany, 2Cell Biology Program, European Molecular Biology Laboratory, D-690 12 Heidelberg, Germany, and 3Center for Human Genetics, 3000 Leuven, Belgium The aim of this study was to investigate the proteolytic pro- containing C-terminal fragments (1 O-l 2 kDa) intracellularly. cessing of the amyloid precursor protein (APP) in polarized Radiosequencing showed that these fragments were created at primary cultures of hippocampal neurons. We have used the a previously described p-secretase cleavage site and at a Semliki Forest virus (SFV) vector to express human APP695 in cleavage site 12 residues from the N terminus of the pA4 hippocampal neurons, sympathetic ganglia, and glial cells. The domain (ThFa4 of APP695), which we named S-cleavage. latter two cells secrete little or no APP, whereas hippocampal Based on the observation that mature hippocampal neurons neurons secrete two forms of APP695, which differ in sialic acid produce two potentially amyloidogenic fragments and secrete content and in their kinetic appearance in the culture medium. substantial amounts of pA4 when expressing human APP, our In addition, rat hippocampal neurons expressing human APP results strengthen the hypothesis that neurons play a central produced significant amounts of the 4 kDa peptide pA4. After 3 role in the process of PA4 deposition in cases of Alzheimer’s hr of metabolic labeling, the relative amount of PA4 peptide to disease and in aged primates.
    [Show full text]
  • Reciprocal Modulation Between Amyloid Precursor Protein and Synaptic Membrane Cholesterol Revealed by Live Cell Imaging T
    Neurobiology of Disease 127 (2019) 449–461 Contents lists available at ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Reciprocal modulation between amyloid precursor protein and synaptic membrane cholesterol revealed by live cell imaging T Claire E. DelBovea, Claire E. Strothmanb, Roman M. Lazarenkoa, Hui Huangc, ⁎ Charles R. Sandersc,d, Qi Zhanga,e, a Department of Pharmacology, Vanderbilt University, United States of America b Department of Cell and Developmental Biology, Vanderbilt University, United States of America c Department of Biochemistry, Vanderbilt University, United States of America d Department of Medicine, Vanderbilt University Medical Center, United States of America e Brain Institute, Florida Atlantic University, United States of America ARTICLE INFO ABSTRACT Keywords: The amyloid precursor protein (APP) has been extensively studied because of its association with Alzheimer's Amyloid precursor protein disease (AD). However, APP distribution across different subcellular membrane compartments and its function Trafficking in neurons remains unclear. We generated an APP fusion protein with a pH-sensitive green fluorescent protein at Proteolysis its ectodomain and a pH-insensitive blue fluorescent protein at its cytosolic domain and used it to measure APP's Membrane distribution, subcellular trafficking, and cleavage in live neurons. This reporter, closely resembling endogenous Cholesterol APP, revealed only a limited correlation between synaptic activities and APP trafficking. However, the synaptic Synapse surface fraction of APP was increased by a reduction in membrane cholesterol levels, a phenomenon that in- volves APP's cholesterol-binding motif. Mutations at or near binding sites not only reduced both the surface fraction of APP and membrane cholesterol levels in a dominant negative manner, but also increased synaptic vulnerability to moderate membrane cholesterol reduction.
    [Show full text]
  • Truncated Β-Amyloid Peptide Channels Provide an Alternative Mechanism for Alzheimer’S Disease and Down Syndrome
    Truncated β-amyloid peptide channels provide an alternative mechanism for Alzheimer’s Disease and Down syndrome Hyunbum Janga,1, Fernando Teran Arceb,1,2, Srinivasan Ramachandranb,1,2, Ricardo Caponeb,2, Rushana Azimovac, Bruce L. Kaganc, Ruth Nussinova,d,3, and Ratnesh Lalb,2,3 aCenter for Cancer Research Nanobiology Program, SAIC-Frederick, Inc., National Cancer Institute, Frederick, MD 21702; bCenter for Nanomedicine and Department of Medicine, University of Chicago, Chicago, IL 60637; cSemel Neuropsychiatric Institute, The David Geffen School of Medicine, University of California at Los Angeles and Greater Los Angeles Veterans Administration Health System, Los Angeles, CA 90024; and dDepartment of Human Molecular Genetics and Biochemistry, The Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel Edited* by Francisco Bezanilla, University of Chicago, Chicago, IL, and approved February 16, 2010 (received for review December 10, 2009) Full-length amyloid beta peptides (Aβ1–40/42) form neuritic amyloid nonamyloidogenic nature, these peptides are assumed to be plaques in Alzheimer’s disease (AD) patients and are implicated in nonpathogenic and these pathways are even being targeted for AD pathology. However, recent transgenic animal models cast doubt AD therapeutics. Significantly, p3 peptides are present in AD on their direct role in AD pathology. Nonamyloidogenic truncated amyloid plaques (17–20), are the main constituent of cerebellar amyloid-beta fragments (Aβ11–42 and Aβ17–42) are also found in amy- preamyloid lesions in Down syndrome (21) and induce neuronal loid plaques of AD and in the preamyloid lesions of Down syndrome, toxicity (22–24). However, their biophysical properties, mecha- a model system for early-onset AD study.
    [Show full text]
  • BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’S Disease Pathology
    Review BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’s Disease Pathology Gerald Koelsch CoMentis, Inc., South San Francisco, CA 94080, USA; [email protected] Received: 15 September 2017; Accepted: 10 October 2017; Published: 13 October 2017 Abstract: Alzheimer’s disease (AD) is a fatal progressive neurodegenerative disorder characterized by increasing loss in memory, cognition, and function of daily living. Among the many pathologic events observed in the progression of AD, changes in amyloid β peptide (Aβ) metabolism proceed fastest, and precede clinical symptoms. BACE1 (β-secretase 1) catalyzes the initial cleavage of the amyloid precursor protein to generate Aβ. Therefore inhibition of BACE1 activity could block one of the earliest pathologic events in AD. However, therapeutic BACE1 inhibition to block Aβ production may need to be balanced with possible effects that might result from diminished physiologic functions BACE1, in particular processing of substrates involved in neuronal function of the brain and periphery. Potentials for beneficial or consequential effects resulting from pharmacologic inhibition of BACE1 are reviewed in context of ongoing clinical trials testing the effect of BACE1 candidate inhibitor drugs in AD populations. Keywords: Alzheimer’s disease; amyloid hypothesis; BACE1; beta secretase; pharmacology 1. Introduction Alzheimer’s disease (AD) is a fatal progressive neurodegenerative disorder, slowly eroding memory, cognition, and functions of daily living, inevitably culminating in death from pneumonia and infectious diseases resulting from failure to thrive, loss of fine motor skills, and incapacitation. Treatment is limited to therapeutics that alleviate symptoms of memory loss, but are effective for a relatively short duration during and after which disease progression continues.
    [Show full text]
  • Dysfunctional Γ-Secretase in Familial Alzheimer's Disease
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Neurochem Manuscript Author Res. Author Manuscript Author manuscript; available in PMC 2019 July 01. Published in final edited form as: Neurochem Res. 2019 January ; 44(1): 5–11. doi:10.1007/s11064-018-2511-1. Dysfunctional γ-secretase in familial Alzheimer’s disease Michael S. Wolfe Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66045 USA. Abstract Genetics strongly implicate the amyloid β-peptide (Aβ) in the pathogenesis of Alzheimer’s disease. Dominant missense mutation in the presenilins and the amyloid precursor protein (APP) cause early-onset familial Alzheimer’s disease (FAD). As presenilin is the catalytic component of the γ-secretase protease complex that produces Aβ from APP, mutation of the enzyme or substrate that produce Aβ leads to FAD. However, the mechanism by which presenilin mutations cause FAD has been controversial, with gain of function and loss of function offered as binary choices. This overview will instead present the case that presenilins are dysfunctional in FAD. γ-Secretase is a multi-functional enzyme that proteolyzes the APP transmembrane domain in a complex and processive manner. Reduction in a specific function—the carboxypeptidase trimming of initially formed long Aβ peptides containing most of the transmembrane domain to shorter secreted forms —is an emerging common feature of FAD-mutant γ-secretase complexes. Keywords amyloid; protease; genetics; biochemistry Introduction The deposition of extracellular amyloid plaques and neurofibrillary tangles in the brain are cardinal pathological features of Alzheimer’s disease (AD) (Goedert and Spillantini, 2006). The former are composed primarily of the amyloid β-peptide (Aβ), while the latter are comprised of filaments of the otherwise microtubule-associated protein tau.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Reduced Reelin Expression Accelerates Amyloid-ßplaque
    9228 • The Journal of Neuroscience, July 7, 2010 • 30(27):9228–9240 Neurobiology of Disease Reduced Reelin Expression Accelerates Amyloid-␤ Plaque Formation and Tau Pathology in Transgenic Alzheimer’s Disease Mice Samira Kocherhans,1* Amrita Madhusudan,1* Jana Doehner,1* Karin S. Breu,1 Roger M. Nitsch,2 Jean-Marc Fritschy,1 and Irene Knuesel1 1Institute of Pharmacology and Toxicology, University of Zurich, CH-8057 Zurich, Switzerland, and 2Division of Psychiatry Research, University of Zurich, CH-8008 Zurich, Switzerland In addition to the fundamental role of the extracellular glycoprotein Reelin in neuronal development and adult synaptic plasticity, alterations in Reelin-mediated signaling have been suggested to contribute to neuronal dysfunction associated with Alzheimer’s disease (AD). In vitro data revealed a biochemical link between Reelin-mediated signaling, Tau phosphorylation, and amyloid precursor protein (APP) processing. To directly address the role of Reelin in amyloid-␤ plaque and Tau pathology in vivo, we crossed heterozygous Reelin knock-out mice (reeler) with transgenic AD mice to investigate the temporal and spatial AD-like neuropathology. We demonstrate that a reduction in Reelin expression results in enhanced amyloidogenic APP processing, as indicated by the precocious production of amyloid-␤ peptides, the significant increase in number and size of amyloid-␤ plaques, as well as age-related aggravation of plaque pathology in double mutant compared with single AD mutant mice of both sexes. Numerous amyloid-␤ plaques accumulate in the hippocampal formation and neocortex of double mutants, precisely in layers with strongest Reelin expression and highest accumulation of Reelin plaques in aged wild-type mice. Moreover, concentric accumulations of phosphorylated Tau-positive neurons around amyloid-␤ plaques were evident in 15-month-old double versus single mutant mice.
    [Show full text]
  • Evaluating the Potential Therapeutic Role of Angiotensin Converting
    Evaluating the Potential Therapeutic Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Alzheimer’s Disease using a Drosophila Model by Sarah Gomes A thesis submitted in conformity with the requirements for the degree of Master of Science Institute of Medical Science University of Toronto © Copyright by Sarah Gomes 2017 Evaluating the Potential Therapeutic Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Alzheimer’s Disease using a Drosophila Model Sarah Gomes Master of Science Institute of Medical Science University of Toronto 2017 Abstract Presenilins (PS) play a role in familial Alzheimer’s disease (AD) and Notch signalling. In a genetic screen looking for modifiers of APP but not Notch, we identified Drosophila orthologs of Angiotensin Converting Enzyme (ACE). Interestingly, ACE polymorphisms are associated with AD and Apo-E, the best characterized risk factor for late-onset AD. Moreover, ACE inhibitors (ACE-I) delayed the onset of cognitive impairment and neurodegeneration in mice and humans. However, it remains unclear why ACE-I are beneficial in AD. Here, we explore the link between PS and ACE in a Drosophila model using genetics and pharmacology. We found that ACE disruption does not affect Notch related phenotypes. Moreover, we found that ACE-I and Angiotensin Receptor Blockers are beneficial in an AD Drosophila model. Since inhibition of ACE has no detrimental effects on Notch and modulates AD related phenotypes, it could provide an important therapeutic target for AD. ii Acknowledgments I would like to begin by thanking my supervisor, Gabrielle Boulianne, for her support and guidance. She has not only taught me how to think like a scientist, but also how to create a work- life balance.
    [Show full text]
  • Ubiquitinations in the Notch Signaling Pathway
    Int. J. Mol. Sci. 2013, 14, 6359-6381; doi:10.3390/ijms14036359 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Ubiquitinations in the Notch Signaling Pathway Julien Moretti 1 and Christel Brou 2,* 1 Immunology Institute, Department of Medicine, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA; E-Mail: [email protected] 2 Institut Pasteur and CNRS URA 2582, Signalisation Moléculaire et Activation Cellulaire, 25 rue du Docteur Roux, 75724 Paris cedex 15, France * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +33-1-40-61-30-41 Fax: +33-1-40-61-30-40. Received: 1 February 2013; in revised form: 11 March 2013 / Accepted: 14 March 2013 / Published: 19 March 2013 Abstract: The very conserved Notch pathway is used iteratively during development and adulthood to regulate cell fates. Notch activation relies on interactions between neighboring cells, through the binding of Notch receptors to their ligands, both transmembrane molecules. This inter-cellular contact initiates a cascade of events eventually transforming the cell surface receptor into a nuclear factor acting on the transcription of specific target genes. This review highlights how the various processes undergone by Notch receptors and ligands that regulate the pathway are linked to ubiquitination events. Keywords: Notch; ubiquitination; deubiquitinating enzyme; signal transduction; trafficking 1. Introduction Development and maintenance of organs and tissues requires constant interaction and communication between cells. One of the major signaling pathways involved in cell-cell communication is the Notch pathway. This pathway is highly conserved in animals as distantly related as C.
    [Show full text]
  • Γ-Secretase Inhibitors for Treating Alzheimer's Disease
    Review: Clinical Trial Outcomes g-secretase inhibitors for treating Alzheimer’s disease: rationale and clinical data Clin. Invest. (2011) 1(8), 1175–1194 There are no drugs available for slowing down the rate of deterioration Francesco Panza†1, Vincenza Frisardi2, of patients with Alzheimer’s disease (AD). With the aim of altering the Bruno P Imbimbo3, Davide Seripa1, natural history of the disease, the pharmaceutical industry has designed Vincenzo Solfrizzi2 & Alberto Pilotto4 and developed several compounds inhibiting g-secretase, the enzymatic 1Geriatric Unit & Gerontology–Geriatric Research Laboratory, IRCCS Casa Sollievo della Sofferenza, complex generating b-amyloid (Ab) peptides (Ab1–40 and Ab1–42), believed to be involved in the pathophysiological cascade of AD, from amyloid precursor Viale Cappuccini 1, 71013 San Giovanni Rotondo, protein (APP). This article briefly reviews the profile of g-secretase inhibitors Foggia, Italy 2Department of Geriatrics, Center for Aging that have reached the clinic. Studies in both transgenic and nontransgenic Brain, Memory Unit, University of Bari, Bari, Italy animal models of AD have indicated that g-secretase inhibitors, administered 3Research & Development Department, by the oral route, are able to lower brain Ab concentrations. However, Chiesi Farmaceutici, Parma, Italy few data are available on the effects of these compounds on brain Ab 4Geriatrics Unit, Azienda, ULSS 16 Padova, Italy † deposition after prolonged administration. g-secretase inhibitors may cause Author for correspondence: Tel.: +39 088 241 6260 abnormalities in the gastrointestinal tract, thymus, spleen, skin, and decrease Fax: +39 088 241 6264 in lymphocytes and alterations in hair color in experimental animals and in E-mail: [email protected] man, effects believed to be associated with the inhibition of the cleavage of Notch, a transmembrane receptor involved in regulating cell-fate decisions.
    [Show full text]
  • Regulated Signaling and Alzheimer's Disease
    Chapter 4 γ-Secretase — Regulated Signaling and Alzheimer's Disease Kohzo Nakayama, Hisashi Nagase, Chang-Sung Koh and Takeshi Ohkawara Additional information is available at the end of the chapter http://dx.doi.org/10.5772/54230 1. Introduction Alzheimer’s disease (AD) is an incurable and progressive neurodegenerative disorder and the most common form of dementia that occurs with aging. The main hallmarks of this disease are the extracellular deposition of amyloid plaques and the intracellular aggregation of tangles in the brain [1, 2]. Although the causes of both the onset and progression of AD are still uncertain, much evidence, including results of genetic analysis, indicates that amyloid precursor protein (APP) itself and its proteolytic processing are responsible for AD. Indeed, familial forms of AD (FAD) have mutations [3] or a duplication of the APP gene [4] or mutations in the presenilin1 or 2 (PS1 or PS2) genes [5-7] that code for a catalytic component of the γ-secretase complex [8]. Although APP plays a central role in AD [1, 2], the physiological function of this membrane protein is not clear [9]. On the other hand, γ-secretase was first identified as a protease that cleaves APP within the transmembrane domain and produces amyloid-β (Aβ) peptides [10], which are the main constituent of amyloid plaques and are thought to be involved in AD pathogenesis. However, similar to the physiological functions of APP, those of γ-secretase are also still unclear [11, 12]. The signaling hypothesis suggests that the primary function of γ-secretase is to regulate signal‐ ing of type 1 membrane proteins (the amino terminus is extracellular, and the carboxy terminus is cytoplasmic); this was proposed by analogy of Notch signaling [13-15].
    [Show full text]
  • CSF-Apoer2 Fragments As a Read-Out of Reelin Signaling Distinct Patterns
    Clinica Chimica Acta 490 (2019) 6–11 Contents lists available at ScienceDirect Clinica Chimica Acta journal homepage: www.elsevier.com/locate/cca CSF-ApoER2 fragments as a read-out of reelin signaling: Distinct patterns in T sporadic and autosomal-dominant Alzheimer disease Inmaculada Lopez-Fonta,b,1, Guillermo Iborra-Lazaroa,b,1, Raquel Sánchez-Vallec, ⁎ ⁎ José-Luis Molinuevoc, Inmaculada Cuchillo-Ibañeza,b, , Javier Sáez-Valeroa,b, a Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, 03550 Sant Joan d'Alacant, Spain b Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain c Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, 08036 Barcelona, Spain ARTICLE INFO ABSTRACT Keywords: Reelin is a glycoprotein associated with synaptic plasticity and neurotransmission. The malfunctioning of reelin Reelin signaling in the brain is likely to contribute to the pathogenesis of Alzheimer's disease (AD). Reelin binding to ApoER2 Apolipoprotein E receptor 2 (ApoER2) activates downstream signaling and induces the proteolytic cleavage of Proteolytic fragment ApoER2, resulting in the generation of soluble fragments. To evaluate the efficiency of reelin signaling in AD,we CSF have quantified the levels of reelin and soluble ectodomain fragments of ApoER2 (ectoApoER2) inthecere- Autosomal-dominant AD brospinal fluid (CSF). CSF from sporadic AD patients (sAD; n = 14, age 54–83 years) had lower levels of ecto- Sporadic AD ApoER2 (~31% reduction; p = .005) compared to those in the age-matched controls (n = 10, age 61–80), and a higher reelin/ecto-ApoER2 ratio. In contrast, autosomal dominant AD patients, carriers of PSEN1 mutations (ADAD; n = 7, age 31–49 years) had higher ecto-ApoER2 levels (~109% increment; p = .001) and a lower reelin/ecto-ApoER2 ratio than the non-mutation carriers from the same families (n = 7, age 25–47 years).
    [Show full text]